Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine

•Deutetrabenazine is approved for the treatment of tardive dyskinesia (TD).•Abnormal Involuntary Movement Scale score assesses severity of abnormal movements.•Minimal clinically important change (MCIC) describes a threshold of clinical benefit to patients.•We calculated an MCIC of about −2 for the Abnormal Involuntary Movement Scale in TD.•Deutetrabenazine provides clinically meaningful reductions in abnormal movements.